利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

255 条记录 (耗时 0.024 秒)

    Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
    3.
    发明申请
    Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin 有权
    含有胰岛素和烟雾发生装置的液体气溶胶制剂和产生气雾化胰岛素的方法

    公开(公告)号：US20040223917A1

    公开(公告)日：2004-11-11

    申请号：US10829945

    申请日：2004-04-23

    申请人： Chrysalis Technologies Incorporated

    发明人： Michael Hindle ,  Kenneth A. Cox

    IPC分类号： A61K038/28 ,  A61L009/04

    CPC分类号： A61K9/007 ,  A61K38/28 ,  A61M11/007 ,  A61M11/041 ,  A61M11/042 ,  A61M15/0065 ,  A61M15/008 ,  A61M15/02 ,  A61M15/025 ,  A61M2016/0039 ,  A61M2205/8206 ,  A61M2205/8237

    摘要： Liquid aerosol formulations for generating aerosolized insulin include insulin and at least one high volatility carrier which protects the insulin from thermal degradation during vaporization of the carrier. The carrier can be a mixture of ethanol and water and the liquid aerosol formulation can be propellant free. An aerosol generating device generates the aerosolized insulin by passing the liquid aerosol formulation through a flow passage heated to convert the liquid into a vapor which entrains insulin particles which mix with air to form an aerosol. The insulin particles can be dry insulin particles produced by a hand held inhaler. By controlling the concentration of the insulin in the formulation, the size of the flow passage and/or the amount of heat which heats the flow passage, the aerosol can be provided with a selected mass median aerodynamic diameter of 1 to 3 nullm or less than 1 nullm so as to be delivered to a targeted portion of the lung using the inhaler.

    摘要翻译： 用于产生气雾化胰岛素的液体气溶胶制剂包括胰岛素和至少一种高挥发性载体，其保护胰岛素在载体蒸发期间的热降解。 载体可以是乙醇和水的混合物，液体气溶胶制剂可以不含推进剂。 烟雾发生装置通过使液体气溶胶制剂通过加热的流动通道将液体转化成蒸气，该蒸气夹带与空气混合以形成气溶胶的胰岛素颗粒，产生雾化的胰岛素。 胰岛素颗粒可以是由手持式吸入器产生的干性胰岛素颗粒。 通过控制制剂中胰岛素的浓度，流路的尺寸和/或加热流道的热量，气雾剂可以具有1至3μm或更小的所选质量中值空气动力学直径 1，以便使用吸入器输送到肺的目标部分。

    Treatment of type 1 diabetes with PDE5 inhibitors
    4.
    发明申请
    Treatment of type 1 diabetes with PDE5 inhibitors 审中-公开
    用PDE5抑制剂治疗1型糖尿病

    公开(公告)号：US20040186046A1

    公开(公告)日：2004-09-23

    申请号：US10799191

    申请日：2004-03-12

    申请人： Pfizer Inc

    发明人： Gillian Munro Burgess ,  Earl Michael Gibbs ,  Christopher Peter Wayman

    IPC分类号： A61K038/28 ,  A61K031/505 ,  A61K031/401 ,  A61K031/366

    CPC分类号： A61K31/401 ,  A61K31/00 ,  A61K31/366 ,  A61K31/505 ,  A61K31/519 ,  A61K31/53

    摘要： The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 使用没有实质的PDE2抑制活性的PDE5抑制剂或其药学上可接受的盐在制备用于治疗1型糖尿病的药物中的用途。 一种在1型糖尿病个体中治疗1型糖尿病的方法，该方法包括向所述个体施用有效量的不具有实质性PDE2抑制活性的PDE5抑制剂或其药学上可接受的盐。

    Treatment of diabetes with rosiglitazone and insulin
    7.
    发明申请
    Treatment of diabetes with rosiglitazone and insulin 审中-公开
    用罗格列酮和胰岛素治疗糖尿病

    公开(公告)号：US20040106543A1

    公开(公告)日：2004-06-03

    申请号：US10722205

    申请日：2003-11-25

    申请人： SmithKline Beecham p.l.c.

    发明人： Stephen Alistair Smith

    IPC分类号： A61K038/28 ,  A61K031/4439

    CPC分类号： A61K38/28 ,  A61K2300/00

    摘要： A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin to a mammal in need thereof.

    摘要翻译： 一种用于治疗哺乳动物的糖尿病和与糖尿病有关的病症的方法，所述方法包括向有需要的哺乳动物施用有效的无毒和可药用量的化合物（I）和胰岛素。

    Method for production of insulin containing oil-based preparation for oral
    8.
    发明申请
    Method for production of insulin containing oil-based preparation for oral 有权
    口服含有油基制剂的胰岛素生产方法

    公开(公告)号：US20040097410A1

    公开(公告)日：2004-05-20

    申请号：US10474474

    申请日：2003-10-08

    发明人： Changxue Zheng ,  Mingxing Duan ,  Hong Ma ,  Houseng Zhong

    IPC分类号： A61K038/28

    CPC分类号： A61K9/107 ,  A61K38/28 ,  Y10S514/938

    摘要： The invention relates to the method for preparation of orally administrated insulin oil formulation comprising: dissolving an amount of insulin in an acidic aqueous buffer (A); adding A to liquid surfactant, the HLB value of which is between 10 and 20, with agitation to form a homogeneous solution (B); adding B to an oil, the HLB value of which is between 0 and 10, with agitation to form oil formulation. This invention has a simple process with low cost. After orally administrated, the formulation prepared with the process of the invention can resist the gastrointestinal degradation by digestive enzymes, and is easily absorbed for hypoglycemic effect.

    摘要翻译： 本发明涉及口服给药的胰岛素油制剂的制备方法，包括：将一定量的胰岛素溶解在酸性水性缓冲液（A）中; 将A加入到液体表面活性剂中，HLB值在10和20之间，搅拌形成均匀溶液（B）; 将B加入到油中，其HLB值在0和10之间，同时搅拌形成油配方。 本发明具有成本低的简单方法。 口服给药后，用本发明方法制备的制剂可抵抗消化酶引起的胃肠道降解，容易被降血糖作用吸收。

    Methods for treatment of diabetes using peptide analogues of insulin
    10.
    发明申请
    Methods for treatment of diabetes using peptide analogues of insulin 失效
    使用胰岛素的肽类似物治疗糖尿病的方法

    公开(公告)号：US20040082503A1

    公开(公告)日：2004-04-29

    申请号：US10339160

    申请日：2003-01-08

    申请人： Neurocrine Biosciences, Inc.

    发明人： Amitabh Gaur ,  Nicholas Ling ,  Paul J. Conlon

    IPC分类号： A61K038/28 ,  C07K014/62

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/62 ,  C07K14/622

    摘要： The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.

    摘要翻译： 本发明涉及胰岛素B链的肽类似物，其通常衍生自包含天然B链序列的残基9至23的肽。 类似物从位置12,13,15和/或16处的天然序列改变，并且可以另外在位置19和/或其他位置改变。 提供了含有这些肽类似物的药物组合物。 肽类似物可用于治疗和抑制糖尿病的发展。